These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29392513)

  • 1. Polymorphic and Covalent Transformations of Gabapentin in Binary Excipient Mixtures after Milling-Induced Stress.
    Tinmanee R; Stamatis SD; Ueyama E; Morris KR; Kirsch LE
    Pharm Res; 2018 Feb; 35(2):39. PubMed ID: 29392513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of gabapentin polymorphs in gabapentin/excipient mixtures using solid state
    Tinmanee R; Larsen SC; Morris KR; Kirsch LE
    J Pharm Biomed Anal; 2017 Nov; 146():29-36. PubMed ID: 28843174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of some hydrophilic excipients on the rate of gabapentin and baclofen lactamization in lyophilized formulations.
    Cutrignelli A; Denora N; Lopedota A; Trapani A; Laquintana V; Latrofa A; Trapani G; Liso G
    Int J Pharm; 2007 Mar; 332(1-2):98-106. PubMed ID: 17071027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miniaturized approach for excipient selection during the development of oral solid dosage form.
    Raijada D; Müllertz A; Cornett C; Munk T; Sonnergaard J; Rantanen J
    J Pharm Sci; 2014 Mar; 103(3):900-8. PubMed ID: 24436033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glass Transition Dynamics and Physical Stability of Amorphous Griseofulvin in Binary Mixtures with Low-
    Tu W; Knapik-Kowalczuk J; Chmiel K; Paluch M
    Mol Pharm; 2019 Aug; 16(8):3626-3635. PubMed ID: 31287704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation of pharmaceutical compounds upon milling and comilling: the role of T(g).
    Descamps M; Willart JF; Dudognon E; Caron V
    J Pharm Sci; 2007 May; 96(5):1398-407. PubMed ID: 17455353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemometric study of the excipients' influence on polymorphic-behavior. Mefenamic acid as case of study.
    Antonio M; Calvo NL; Maggio RM
    J Pharm Biomed Anal; 2019 Jun; 170():8-15. PubMed ID: 30901720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Polymer Type and Relative Humidity on the Long-Term Physical Stability of Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Heinzerling O; Degenhardt M; Sadowski G
    Mol Pharm; 2017 Dec; 14(12):4374-4386. PubMed ID: 29050468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid-state transformation of different gabapentin polymorphs upon milling and co-milling.
    Lin SY; Hsu CH; Ke WT
    Int J Pharm; 2010 Aug; 396(1-2):83-90. PubMed ID: 20561572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigating unwanted amorphisation: A screening method for the selection of suitable excipients.
    Amharar Y; Curtin V; Gallagher KH; O'Siochru E; O'Connell P; Healy AM
    Eur J Pharm Sci; 2016 Jan; 81():181-8. PubMed ID: 26493586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting Excipients Forming Therapeutic Deep Eutectic Systems-A Mechanistic Approach.
    Wolbert F; Brandenbusch C; Sadowski G
    Mol Pharm; 2019 Jul; 16(7):3091-3099. PubMed ID: 31095911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The stress stability of olanzapine: studies of interactions with excipients in solid state pharmaceutical formulations.
    Djordjević Filijović N; Antonijević MD; Pavlović A; Vučković I; Nikolić K; Agbaba D
    Drug Dev Ind Pharm; 2015 Mar; 41(3):502-14. PubMed ID: 24611817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solubility and dissolution rate enhancement of ibuprofen by co-milling with polymeric excipients.
    Hussain A; Smith G; Khan KA; Bukhari NI; Pedge NI; Ermolina I
    Eur J Pharm Sci; 2018 Oct; 123():395-403. PubMed ID: 30076953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Excipient Interactions in the Solid State: The Role of Different Stress Factors.
    Gressl C; Brunsteiner M; Davis A; Landis M; Pencheva K; Scrivens G; Sluggett GW; Wood GPF; Gruber-Woelfler H; Khinast JG; Paudel A
    Mol Pharm; 2017 Dec; 14(12):4560-4571. PubMed ID: 29058913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-excipient compatibility testing using a high-throughput approach and statistical design.
    Wyttenbach N; Birringer C; Alsenz J; Kuentz M
    Pharm Dev Technol; 2005; 10(4):499-505. PubMed ID: 16370179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical steps during the prilling process of molten lipids: Main stumbling blocks due to pharmaceutical excipient properties.
    Séquier F; Faivre V; Lanne JY; Daste G; Renouard M; Lesieur S
    Int J Pharm; 2020 Feb; 576():119036. PubMed ID: 31953083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement.
    Sanganwar GP; Sathigari S; Babu RJ; Gupta RB
    Eur J Pharm Sci; 2010 Jan; 39(1-3):164-74. PubMed ID: 19961931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical stability of crystal hydrates and their anhydrates in the presence of excipients.
    Salameh AK; Taylor LS
    J Pharm Sci; 2006 Feb; 95(2):446-61. PubMed ID: 16380975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives.
    Balani PN; Ng WK; Tan RB; Chan SY
    J Pharm Sci; 2010 May; 99(5):2462-74. PubMed ID: 19902526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals.
    Yoshioka S; Aso Y
    J Pharm Sci; 2007 May; 96(5):960-81. PubMed ID: 17455355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.